Patents by Inventor Jonathan L. Sessler

Jonathan L. Sessler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5587478
    Abstract: The present invention provides novel sapphyrin dimers, trimers, oligomers and polymers, which multimers may include repeating units of sapphyrin or sapphyrin derivatives alone, or may further incorporate other units such as nucleobases.
    Type: Grant
    Filed: March 15, 1995
    Date of Patent: December 24, 1996
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jonathan L. Sessler, Vladimir Kr al, Andrei Andrievsky
  • Patent number: 5587371
    Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O.sub.2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: December 24, 1996
    Assignees: Pharmacyclics, Inc., Board of Trustees, Univ. of TX Sys.
    Inventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi, Vladimir A. Kr al, Darren Magda
  • Patent number: 5583220
    Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O.sub.2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: December 10, 1996
    Assignees: Pharmacyclics, Inc., Board of Trustees, Univ. of TX Sys.
    Inventors: Jonathan L. Sessler, Anthony M. Harriman, Richard A. Miller, Tarak D. Mody, Gregory W. Hemmi, Vladimir A. Kral, Darren Magda
  • Patent number: 5580543
    Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O.sub.2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: December 3, 1996
    Assignees: Pharmacyclics, Inc., Board of Regents, Univ. of Texas Sys.
    Inventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi, Vladimir A. Kr al, Darren Magda
  • Patent number: 5569759
    Abstract: The present invention involves water soluble hydroxy-substituted texaphyrins retaining lipophilicity, the synthesis of such compounds and their uses. These expanded porphyrin-like macrocycles are efficient chelators of divalent and trivalent metal ions. Various metal (e.g., transition, main group, and lanthanide) complexes of the hydroxy-substituted texaphyrin derivatives of the present invention have unusual water solubility and stability. They absorb light strongly in a physiologically important region (i.e. 690-880 nm). They have enhanced relaxivity and therefore are useful in magnetic resonance imaging. They form long-lived triplet states in high yield and act as photosensitizers for the generation of singlet oxygen. Thus, they are useful for inactivation or destruction of enveloped viruses, mononuclear or other cells infected with such viruses as well as tumor cells.
    Type: Grant
    Filed: July 28, 1993
    Date of Patent: October 29, 1996
    Assignee: Board of Regents, University of Texas System
    Inventors: Jonathan L. Sessler, Gregory W. Hemmi, Tarak D. Mody
  • Patent number: 5567687
    Abstract: A texaphyrin having substituents containing ethoxy groups, methods for using texaphyrins in photodynamic therapy, and cleavage of a polymer of deoxyribonucleic acid are disclosed. The in vivo treatment of tumors and atheroma is demonstrated using Lu(III)texaphyrin complexes. A preferred method of use is the site-specific cleavage of a polymer of deoxyribonucleic acid and a preferred texaphyrin is a derivatized texaphyrin having binding specificity, in particular, a texaphyrin covalently coupled to a site-directing molecule, preferably an oligonucleotide.
    Type: Grant
    Filed: September 21, 1994
    Date of Patent: October 22, 1996
    Assignees: University of Texas, Pharmacyclics, Inc.
    Inventors: Darren Magda, Jonathan L. Sessler, Brent Iverson, Petra L. Jansen, Meredith Wright, Tarak D. Mody, Gregory W. Hemmi
  • Patent number: 5565552
    Abstract: The invention is directed to a method of incorporating expanded porphyrins, and particularly of incorporating a sapphyrin or a texaphyrin, before, during, or after chemical synthesis of an oligomer to form an expanded porphyrin-oligonucleotide conjugate, and particularly a sapphyrin- or texaphyrin-oligonucleotide conjugate. This method includes reacting derivatized nucleotides and a sapphyrin or a texaphyrin in a desired order in an automated or manual DNA synthesizer having a solid support to form a sapphyrin- or a texaphyrin-oligonucleotide conjugate.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 15, 1996
    Assignees: Pharmacyclics, Inc., Board of Regents, Univ. of Texas Sys.
    Inventors: Darren Magda, Jonathan L. Sessler, Brent L. Iverson, Petra I. Sansom, Shaun P. Crofts
  • Patent number: 5559207
    Abstract: A method of phosphate ester hydrolysis including incubating a solution of an aqueous phosphate ester with a texaphyrin metal complex. The metal is a metal cation having catalytic activity for ester bond hydrolysis in aqueous solution, in particular, a lanthanide metal cation, preferably Eu(III) or Dy(III). A preferred substrate is RNA and a preferred texaphyrin is a derivatized texaphyrin having binding specificity, in particular, a texaphyrin covalently coupled to a site-directed molecule, preferably an oligonucleotide.
    Type: Grant
    Filed: April 14, 1994
    Date of Patent: September 24, 1996
    Assignees: Board of Regents, University of Texas, Pharmacyclics, Inc.
    Inventors: Jonathan L. Sessler, Daniel A. Smith, Richard A. Miller, Kevin L. Ross, Meredith Wright, William C. Dow, Vladimir A. Kr al, Brent Iverson, Darren Magda
  • Patent number: 5543514
    Abstract: Sapphyrins are provided having appended functional groups that render the sapphyrin water-soluble. Such water-soluble sapphyrins are useful for photodynamic therapy, for example.
    Type: Grant
    Filed: April 6, 1995
    Date of Patent: August 6, 1996
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jonathan L. Sessler, Vladimir Kral
  • Patent number: 5530123
    Abstract: The present invention provides various covalently modified sapphyrin derivatives and conjugates, and also, polymers including sapphyrin or derivatives thereof. Disclosed are water soluble sapphyrins, including polyhydroxysapphyrins and sapphyrin-sugar derivatives; sapphyrin-metal chelating conjugates; sapphyrin nucleobase conjugates; and polymer supported sapphyrins. Novel sapphyrin dimers, trimers, oligomers and polymers are also described, which polymers may include repeating units of sapphyrin or sapphyrin derivatives alone, or may further incorporate other units such as nucleobases.
    Type: Grant
    Filed: October 11, 1994
    Date of Patent: June 25, 1996
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jonathan L. Sessler, Brent L. Iverson, Vladimir Kral, Kevin Shreder, Hiroyuki Furuta
  • Patent number: 5525325
    Abstract: The present invention involves a novel tripyrrole dimethine-derived "expanded porphyrin" (texaphyrin), the synthesis of such compounds, their analogs or derivatives and their uses. These expanded porphyrin-like macrocycles are efficient chelators of divalent and trivalent metal ions. Metal complexes of these compounds are active as photosensitizers for the generation of singlet oxygen and thus potentially for inactivation or destruction of human immunodeficiency virus (HIV-1), mononuclear or other cells infected with such virus and tumor cells as well. A variety of texaphyrin derivatives have been produced and many more are readily obtainable. Various metal (e.g., transition, main group, and lanthanide) complexes with the texaphyrin and texaphyrin derivatives of the present invention have unusual water solubility and stability which render them particularly useful. These metallotexaphyrin complexes have optical properties making them unique as compared to existing porphyrin-like or other macrocycles.
    Type: Grant
    Filed: September 7, 1994
    Date of Patent: June 11, 1996
    Assignee: Board of Regents, University of Texas
    Inventors: Jonathan L. Sessler, Gregory W. Hemmi, Toshiaki Murai
  • Patent number: 5504205
    Abstract: The present invention involves water soluble hydroxy-substituted texaphyrins retaining lipophilicity, the synthesis of such compounds and their uses. These expanded porphyrin-like macrocycles are efficient chelators of divalent and trivalent metal ions. Various metal (e.g., transition, main group, and lanthanide) complexes of the hydroxy-substituted texaphyrin derivatives of the present invention have unusual water solubility and stability. They absorb light strongly in a physiologically important region (i.e. 690-880 nm). They have enhanced relaxivity and therefore are useful in magnetic resonance imaging. They form long-lived triplet states in high yield and act as photosensitizers for the generation of singlet oxygen. Thus, they are useful for inactivation or destruction of human immunodeficiency virus (HIV-1), mononuclear or other cells infected with such virus as well as tumor cells.
    Type: Grant
    Filed: July 26, 1994
    Date of Patent: April 2, 1996
    Assignee: Board of Regents, University of Texas System
    Inventors: Jonathan L. Sessler, Gregory W. Hemmi, Tarak D. Mody
  • Patent number: 5475104
    Abstract: The present invention involves water soluble hydroxy-substituted texaphyrins retaining lipophilicity, the synthesis of such compounds and their uses. These expanded porphyrin-like macrocycles are efficient chelators of divalent and trivalent metal ions. Various metal (e.g., transition, main group, and lanthanide) complexes of the hydroxy-substituted texaphyrin derivatives of the present invention have unusual water solubility and stability. They absorb light strongly in a physiologically important region (i.e. 690-880 nm). They have enhanced relaxivity and therefore are useful in magnetic resonance imaging. They form long-lived triplet states in high yield and act as photosensitizers for the generation of singlet oxygen. Thus, they are useful for inactivation or destruction of human immunodeficiency virus (HIV-1), mononuclear or other cells infected with such virus as well as tumor cells.
    Type: Grant
    Filed: August 25, 1993
    Date of Patent: December 12, 1995
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jonathan L. Sessler, Gregory W. Hemmi, Tarak D. Mody
  • Patent number: 5457195
    Abstract: The present invention provides various covalently modified sapphyrin derivatives and conjugates, and also, polymers including sapphyrin or derivatives thereof. Disclosed are water soluble sapphyrins, including polyhydroxysapphyrins and sapphyrin-sugar derivatives; sapphyrin-metal chelating conjugates; sapphyrin nucleobase conjugates; and polymer supported sapphyrins. Novel sapphyrin dimers, trimers, oligomers and polymers are also described, which polymers may include repeating units of sapphyrin or sapphyrin derivatives alone, or may further incorporate other units such as nucleobases.
    Type: Grant
    Filed: October 21, 1992
    Date of Patent: October 10, 1995
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jonathan L. Sessler, Brent L. Iverson, Vladimir Kral, Kevin Shreder, Hiroyuki Furuta
  • Patent number: 5457183
    Abstract: A method of using texaphyrins as radiosensitizers. Advantageous properties of texaphyrins for use as a radiosensitizer include i) a low redox potential which allows radiation induced solvated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing the hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical which, nevertheless, reacts readily to covalently modify neighboring molecules causing further cellular damage, and iii) intrinsic biolocalization and indifference to the presence of O.sub.2 which allow texaphyrin to be particularly effective for treating the hypoxic areas of solid tumors. Sensitizer enhancement ratios of 1.62 and 2.2 were achieved at 20 .mu.M and 80 .mu.M gadolinium-texaphyrin, respectively, with a mouse leukemia cell line.
    Type: Grant
    Filed: October 12, 1993
    Date of Patent: October 10, 1995
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi, Vladimir Kral
  • Patent number: 5451576
    Abstract: The present invention involves water soluble hydroxy-substituted texaphyrins retaining lipophilicity, the synthesis of such compounds and their uses. These expanded porphyrin-like macrocycles are efficient chelators of divalent and trivalent metal ions. Various metal (e.g., transition, main group, and lanthanide) complexes of the hydroxy-substituted texaphyrin derivatives of the present invention have unusual water solubility and stability. They absorb light strongly in a physiologically important region (i.e. 690-880 nm). They have enhanced relaxivity and therefore are useful in magnetic resonance imaging. They form long-lived triplet states in high yield and act as photosensitizers for the generation of singlet oxygen. Thus, they are useful for inactivation or destruction of human immunodeficiency virus (HIV-1), mononuclear or other cells infected with such virus as well as tumor cells.
    Type: Grant
    Filed: August 25, 1993
    Date of Patent: September 19, 1995
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jonathan L. Sessler, Gregory W. Hemmi, Tarak D. Mody
  • Patent number: 5439570
    Abstract: The present invention involves water soluble hydroxy-substituted texaphyrins retaining lipophilicity, the synthesis of such compounds and their uses. These expanded porphyrin-like macrocycles are efficient chelators of divalent and trivalent metal ions. Various metal (e.g., transition, main group, and lanthanide) complexes of the hydroxy-substituted texaphyrin derivatives of the present invention have unusual water solubility and stability. They absorb light strongly in a physiologically important region (i.e. 690-880 nm). They have enhanced relaxivity and therefore are useful in magnetic resonance imaging. They form long-lived triplet states in high yield and act as photosensitizers for the generation of singlet oxygen. Thus, they are useful for inactivation or destruction of human immunodeficiency virus (HIV-1), mononuclear or other cells infected with such virus as well as tumor cells.
    Type: Grant
    Filed: August 25, 1993
    Date of Patent: August 8, 1995
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jonathan L. Sessler, Gregory W. Hemmi, Tarak D. Mody
  • Patent number: 5432171
    Abstract: The present invention involves water soluble hydroxy-substituted texaphyrins retaining lipophilicity, the synthesis of such compounds and their uses. These expanded porphyrin-like macrocycles are efficient chelators of divalent and trivalent metal ions. Various metal (e.g., transition, main group, and lanthanide) complexes of the hydroxy-substituted texaphyrin derivatives of the present invention have unusual water solubility and stability. They absorb light strongly in a physiologically important region (i.e. 690-880 nm). They have enhanced relaxivity and therefore are useful in magnetic resonance imaging. They form long-lived triplet states in high yield and act as photosensitizers for the generation of singlet oxygen. Thus, they are useful for inactivation or destruction of human immunodeficiency virus (HIV-1), mononuclear or other cells infected with such virus as well as tumor cells.
    Type: Grant
    Filed: July 28, 1993
    Date of Patent: July 11, 1995
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jonathan L. Sessler, Gregory W. Hemmi, Tarak D. Mody
  • Patent number: 5410045
    Abstract: The present invention is directed to the synthesis and use of novel macrocyclic compounds, based upon a new class of expanded porphyrins, termed rubyrins. Disclosed herein is the structure and synthesis of a prototypical rubyrin and various substituted rubyrin analogues, conjugates and compositions. Rubyrin itself is characterized by the presence of six pyrrolic subunits contained within a fully aromatic 26 .pi.-electron macrocyclic framework and by UV/VIS absorption bands that are very red-shifted as compared to those of other porphyrins or pentapyrrolic expanded porphyrins. The rubyrin-type class of compounds is further characterized by an ability to undergo facile protonation at the pyrrolic nitrogens and, once protonated, by an ability to form complexes with anions such as nucleotide-containing compounds. Rubyrin-based compounds are useful as, for example, anion chelators and receptors and as transporters for various anionic compounds including antiviral agents. In addition to the 26 .pi.
    Type: Grant
    Filed: February 9, 1993
    Date of Patent: April 25, 1995
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jonathan L. Sessler, Takashi Morishima, Steven J. Weghorn
  • Patent number: 5369101
    Abstract: The present invention involves a novel tripyrrole dimethine-derived "expanded porphyrin" (texaphyrin), the synthesis of such compounds, their analogs or derivatives and their uses. These expanded porphyrin-like macrocycles are efficient chelators of divalent and trivalent metal ions. Metal complexes of these compounds are active as photosensitizers for the generation of singlet oxygen and thus potentially for inactivation or destruction of human immunodeficiency virus (HIV-1), mononuclear or other cells infected with such virus and tumor cells as well. A variety of texaphyrin derivatives have been produced and many more are readily obtainable. Various metal (e.g., transition, main group, and lanthanide) complexes with the texaphyrin and texaphyrin derivatives of the present invention have unusual water solubility and stability which render them particularly useful. These metallotexaphyrin complexes have optical properties making them unique as compared to existing porphyrin-like or other macrocycles.
    Type: Grant
    Filed: December 16, 1993
    Date of Patent: November 29, 1994
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jonathan L. Sessler, Gregory W. Hemmi, Toshiaki Murai